Bristol Myers Squibb (BMY) EBT (2016 - 2026)

Bristol Myers Squibb has reported EBT over the past 18 years, most recently at $3.2 billion for Q1 2026.

Quarterly EBT rose 9.05% to $3.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.6 billion through Mar 2026, up 57.12% year-over-year, with the annual reading at $9.3 billion for FY2025, 211.33% up from the prior year.
EBT was $3.2 billion for Q1 2026 at Bristol Myers Squibb, up from $1.5 billion in the prior quarter.
Over five years, EBT peaked at $3.2 billion in Q1 2026 and troughed at -$11.5 billion in Q1 2024.
The 5-year median for EBT is $1.9 billion (2022), against an average of $1.2 billion.
Year-over-year, EBT tumbled 515.74% in 2024 and then surged 740.0% in 2025.
A 5-year view of EBT shows it stood at $1.9 billion in 2022, then dropped by 9.95% to $1.7 billion in 2023, then crashed by 89.55% to $175.0 million in 2024, then surged by 740.0% to $1.5 billion in 2025, then skyrocketed by 120.41% to $3.2 billion in 2026.
Per Business Quant, the three most recent readings for BMY's EBT are $3.2 billion (Q1 2026), $1.5 billion (Q4 2025), and $3.1 billion (Q3 2025).

Peer Comparison